Disclosed herein are methods and systems for rapid detection of microorganisms such as bacteria in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene encoding one subunit of an indicator protein. The specificity of the bacteriophage allows detection of a particular bacteria of interest and an indicator signal may be amplified to optimize assay sensitivity.

Disclosed herein are methods and systems for rapid detection of microorganisms such as bacteria in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene encoding one subunit of an indicator protein. The specificity of the bacteriophage allows detection of a particular bacteria of interest and an indicator signal may be amplified to optimize assay sensitivity.

Highly sensitive assays for pathogen detection, identification and/or analysis including, but not limited to, sensing of metabolite patterns associated with high-risk drug resistance phenotypes.

There are provided a urine testing apparatus and a urine testing method which can stabilize urine vitamins for several days and improve testing accuracy and convenience of a urine collection test of a subject. According to this urine testing apparatus, the inner wall surface of a urine collection storage container is coated with an aqueous citric acid solution or the like as a urine stabilizer. Alternatively, a dried or freeze-dried aqueous citric acid solution or the like as the urine stabilizer is stored in the urine collection storage container. On the other hand, according to the urine testing method of this invention, the aqueous citric acid solution or the like as the urine stabilizer is added to the collected urine sample, the vitamin concentration of at least 7 days after urine collection is stabilized to stabilize each urine vitamin for several days, thereby improving the convenience of the urine collection test of the subject. In particular, the urine concentrations of vitamins B can be stabilized to accurately test the nutrients lacking in the body of the subject.

There are provided a urine testing apparatus and a urine testing method which can stabilize urine vitamins for several days and improve testing accuracy and convenience of a urine collection test of a subject. According to this urine testing apparatus, the inner wall surface of a urine collection storage container is coated with an aqueous citric acid solution or the like as a urine stabilizer. Alternatively, a dried or freeze-dried aqueous citric acid solution or the like as the urine stabilizer is stored in the urine collection storage container. On the other hand, according to the urine testing method of this invention, the aqueous citric acid solution or the like as the urine stabilizer is added to the collected urine sample, the vitamin concentration of at least 7 days after urine collection is stabilized to stabilize each urine vitamin for several days, thereby improving the convenience of the urine collection test of the subject. In particular, the urine concentrations of vitamins B can be stabilized to accurately test the nutrients lacking in the body of the subject.

The present invention relates to the field of diagnostics and, more in particular, to MRI activatable contrast agents and compositions thereof for the detection of nuclease activity, wherein said nuclease activity is caused by microbial infection or by nuclease activity related to cancer, particularly colon cancer or pancreatic cancer. Activatable contrast agents for MRI have been developed, wherein the oligonucleotide is flanked by a paramagnetic and a superparamagnetic agent, and thus providing magnetic quenching. Moreover, the oligonucleotide has regions that confer resistance to mammalian endonucleases and sensitivity to microbial endonucleases. When the activatable contrast agent of the invention is in the presence of microbial nuclease activity or a tumour cell nuclease activity, the oligonucleotide is cleaved, agents are unquenched, and the signal derived from the activated contrast agent is detected by MRI.

The present invention aims at providing a specific antibody that can simply and rapidly detect Mycoplasma pneumoniae which is a causative bacterium of mycoplasma pneumonia, with high sensitivity, and also an immunological detection method and a kit containing the same antibody. The present invention makes it possible to diagnose infection with Mycoplasma pneumoniae more rapidly and specifically than the conventional method, by producing an antibody recognizing a specific epitope of P30 protein of Mycoplasma pneumoniae and performing an immunological detection using the antibody. Also, the present invention enables easy and rapid detection of Mycoplasma pneumoniae and diagnosis of infection with the same at a hospital or the like without need of specialized instruments or skilled techniques.

The present invention aims at providing a specific antibody that can simply and rapidly detect Mycoplasma pneumoniae which is a causative bacterium of mycoplasma pneumonia, with high sensitivity, and also an immunological detection method and a kit containing the same antibody. The present invention makes it possible to diagnose infection with Mycoplasma pneumoniae more rapidly and specifically than the conventional method, by producing an antibody recognizing a specific epitope of P30 protein of Mycoplasma pneumoniae and performing an immunological detection using the antibody. Also, the present invention enables easy and rapid detection of Mycoplasma pneumoniae and diagnosis of infection with the same at a hospital or the like without need of specialized instruments or skilled techniques.

The present invention provides a method for the quantification of virus particles in a biological sample, comprising the steps of: (a) introducing said biological sample comprising virus particles into a capillary tube containing a buffer solution; (b) applying an electrical field to said capillary tube of sufficient voltage to allow for the separation of the virus particles from additional constituents in said sample, to obtain electrophoretical fractions; (c) generating an electropherogram associated with the electrophoretical fractions; and (d) determining the concentration of virus particles in said sample by comparing the electropherogram with an electropherogram generated from a reference sample containing a known concentration of said virus particles.

The present invention provides a method for the quantification of virus particles in a biological sample, comprising the steps of: (a) introducing said biological sample comprising virus particles into a capillary tube containing a buffer solution; (b) applying an electrical field to said capillary tube of sufficient voltage to allow for the separation of the virus particles from additional constituents in said sample, to obtain electrophoretical fractions; (c) generating an electropherogram associated with the electrophoretical fractions; and (d) determining the concentration of virus particles in said sample by comparing the electropherogram with an electropherogram generated from a reference sample containing a known concentration of said virus particles.